Engineered T cell receptors and immune therapy using the same

US10618956B2 · kind B2 · utility

Assignee

• Immatics Biotechnologies GmbH · DE

Inventors

• Felix UNVERDORBEN · Rötteln, DE
• Sebastian BUNK · Wien, AT
• Martin Hofmann · Lörrach, DE
• Dominik MAURER · Lingen (Ems), DE
• Meike HUTT · Stuttgart, DE
• Claudia WAGNER · Lörrach, DE
• Leonie ALTEN · Lörrach, DE

Key dates

• Filing date: Nov 5, 2018
• Grant date: Apr 14, 2020
• Expiry date: Nov 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.